NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/15/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,393.25 mln
Float80.98 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
95.20
Strong upside
Relative Strength
88
/ 100
Strongly outperforming
Debt / Equity
0.00
Debt-free
ROE
-32.28
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Spyre Therapeutics is a clinical-stage biotech company based in Waltham, Massachusetts, focused on creating new treatments for inflammatory bowel disease and rheumatic conditions. The company is advancing several drug candidates that target specific proteins involved in inflammation, including standalone antibodies and combination therapies designed to address conditions such as ulcerative colitis and Crohn's disease. Formerly known as Aeglea BioTherapeutics, the company adopted its current name in November 2023 and has been operating since its founding in 2013.
